Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to see if administering intravenous immune globulin (IVIG)
(putting immune globulin directly into your blood) helps to improve the symptoms of
orthostatic hypotension (sudden fall in blood pressure when a person stands up) and quality
of life in men and women who have autoimmune autonomic ganglionopathy (AAG).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Beth Israel Deaconess Medical Center
Collaborators:
Mayo Clinic National Institute of Neurological Disorders and Stroke (NINDS) New York University School of Medicine NYU Langone Health University of Texas Southwestern Medical Center Vanderbilt University